Nyxoah Raises $52.5 Million in US Public Offering

Nyxoah, a Belgian medical technology company, has recently concluded a public offering in the United States, raising an impressive $52.5 million. This offering involved the sale of over 5 million ordinary shares at $9.25 per share, with additional shares acquired by the underwriters.

The company intends to use the proceeds for various purposes, such as pre-commercialization activities, clinical research initiatives, advancing the Genio system, and meeting general corporate requirements.

Nyxoah specializes in developing solutions for Obstructive Sleep Apnea (OSA), a prevalent sleep disorder. Their flagship product, the Genio system, offers neurostimulation therapy for OSA patients, aiming to enhance their quality of life.

While the Genio system has been CE marked in 2019, its approval for use in the US is still pending regulatory evaluation.

The press release also includes forward-looking statements concerning Nyxoah's projections, clinical trials, regulatory processes, and financial prospects. These statements are subject to uncertainties that may influence the company's actual performance.

Nyxoah's successful public offering marks a significant milestone in their mission to address Obstructive Sleep Apnea through innovative medical technology. With a focus on improving patient outcomes and enhancing quality of life, Nyxoah continues to advance its Genio system, offering hope for individuals affected by this common sleep disorder.